Translational oncogenomics: Toward rational therapeutic decision-making

Current Opinion in Oncology

Volumn 14, Issue 2, 2002, Pages 171-179

  Rosell, Rafael ^a   Monzo, Mariano ^a   O'Brate, Aurora ^a   Taron, Miquel ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT; MESSENGER RNA;

ALLELE; BREAST CANCER; CANCER GENETICS; CANCER RESISTANCE; CANCER SURVIVAL; CPG ISLAND; DNA METHYLATION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HETEROZYGOSITY LOSS; HUMAN; INDIVIDUALIZATION; LUNG NON SMALL CELL CANCER; MEDICAL DECISION MAKING; MICROTUBULE; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING;

DECISION MAKING; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; PHARMACOGENETICS;

EID: 0036130477     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200203000-00006     Document Type: Review

References (75)

1. Global analysis of gene expression in invasion by a lung cancer model
2. Extensive characterization of genetic alterations in a series of human colorectal cancer cell lines
3. Molecular predictors of survival after adjuvant chemotherapy for colon cancer
4. Predictive molecular markers in non-small-cell lung cancer
5. A novel alternative approach for prediction of radiation response of squamous cell carcinoma of head and neck
6. Digital PCR
7. Evidence that genetic instability occurs at an early stage of colorectal tumorigenesis
8. Counting alleles reveals a connection between chromosome 18q loss and vascular invasion
9. Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers
10. Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers
11. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis inducing ligand and express death receptor 4 and death receptor 5
12. Microsatellite alterations at 5q21, 11p13, and 11p15.5 do not predict survival in non-small-cell lung cancer
13. Epigenetic lesions causing genetic lesions in human cancer: Promoter hypermethylation of DNA repair genes
14. Molecular structure of nucleic acids
15. Alterations in DNA methylation: A fundamental aspect of neoplasia
16. A gene hypermethylation profile of human cancer
17. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small-cell lung cancer patients
18. DAP-kinase loss of expression in various carcinoma and B-cell lymphoma cell lines: Possible implications for role as tumor suppressor gene
19. Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer
20. Promoter methylation of DAP-kinase: Association with advanced stage in non-small-cell lung cancer
21. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients
22. Aberrant promoter methylation of multiple genes in non-small-cell lung cancers
23. p16INK4a and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small-cell lung cancer
24. Predicting lung cancer by detecting aberrant promoter methylation in sputum
25. 5′ CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer
26. Loss of Fhit is frequent in stage I non-small-cell lung cancer and in the lungs of chronic smokers
27. Allelic deletion analysis of the FHIT gene predicts poor survival in non-small-cell lung cancer
28. Clinicopathological significance of Fhit protein expression in stage I non-small-cell lung carcinoma
29. Abnormal fragile histidine triad (FHIT) expression in advanced cervical carcinoma: A poor prognostic factor
30. Loss of expression and aberrant methylation of the CDH13 (H-Cadherin) gene in breast and lung carcinomas
31. Methylation patterns of the E-cadherin 5′CpG islands are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression
32. TMS1, a novel proapoptotic caspase recruitment domain protein, is a target of methylation-induced gene silencing in human breast cancers
33. Multiple genetic abnormalities in tumor and paired serum DNA of resected non-small-cell lung cancer patients
34. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3
35. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression
36. Hypermethylation of the CpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene form the 3p21.3 locus, occurs in a large percentage of human breast cancers
37. The CpG island of the novel tumor suppressor gene RASSF1A is intensely methylated in primary small cell lung carcinomas
38. High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma
39. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma
40. Aberrant methylation and simian virus 40 tag sequences in malignant mesothelioma
41. Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas
42. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma
43. Adenomatous polyposis coli gene promoter hypermethylation in non-small-cell lung cancer is associated with survival
44. Promoter methylation and silencing of the retinoic acid receptor-β gene in lung carcinomas
45. Methylation and silencing of the retinoic acid receptor-β2 gene in breast cancer
46. Wildtype Kras2 can inhibit lung carcinogenesis in mice
47. A gene expression database for the molecular pharmacology of cancer
48. Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene-expression profiles
49. S-adenosylmethionine synthetase is overexpressed in murine neuroblastoma cells resistant to nucleoside analogue inhibitors of S-adenosylhomocysteine hydrolase: A novel mechanism of drug resistance
50. Distinct pattern of E2F1 expression in human lung tumours: E2F1 is upregulated in small cell lung carcinoma
51. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small-cell lung cancer
52. Expression of X-linked inhibitor of apoptosis as a novel prognostic marker in radically resected non-small-cell lung cancer patients
53. Sex-specific expression of gastrin-releasing peptide receptor: Relationship to smoking history and risk of lung cancer
54. Women and lung cancer: Does oestrogen play a role?
55. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line
56. Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit
57. Detection of epithelial messenger RNA in the plasma of breast cancer patients is associated with poor prognosis tumor characteristics
58. Free DNA in the serum of cancer patients and the effect of therapy
59. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients
60. Microtubules and signal transduction
61. Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells
62. Antisense oligonucleotides to class III β-tubulin sensitize drug-resistant cell to Taxol
63. The role of β-tubulin isotypes in resistance to antimitotic drugs
64. Expression of β-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-anticancer drug screen: Correlation with sensitivity to microtubule active agents
65. The tumor suppressor protein Fhit
66. Correlation of oncoprotein 18/stathmin expression in human breast cancer with established prognostic factors
67. Oncoprotein 18 overexpression increases the sensitivity to vindesine in the human lung carcinoma cells
68. Taxol and anti-stathmin therapy: A synergistic combination that targets the mitotic spindle
69. Modulation of drug resistance by α-tubulin in paclitaxel-resistant human lung cancer cell lines
70. Transformation and altered signal transduction by a naturally occurring mutant EGF receptor
71. Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters β-tubulin isotype expression
72. Overexpression of IRF9 confers resistance to antimicrotubule agents in breast cancer cells
73. Collapsin response mediator protein-1 and the invasion and metastasis of cancer cells
74. Evidence that collapsin response mediator protein-2 is involved in the dynamics of microtubules
75. Semaphorin SEMA3F localization in malignant human lung and cell lines